IMMUNO GENOMICS BASED BLOOD TEST

TO ASSIST PHYSICIANS UNDERSTAND THE SEVERITY OF DISEASE

Approach

OncoCellMDx is a privately held company dedicated to the development and commercialization of novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School.  In particular, we have developed a noninvasive blood-based immunogenomic assays that will aid the physician to better understand the underlying pathology.  The first product is for assessing the severity of prostate cancer.  Other oncology indications as well as non-oncology indications are part of our pipeline.

The assay is based on examining specific transcription levels between phagocytic and non-phagocytic cells. This proprietary technology and algorithm has allowed us to not only detect disease but to also, and more importantly, guide the physician as to the grade and aggressiveness of the disease.

Our mission is to provide clinicians with quantifiable results that allows professionals to make timely and much more directed medical decisions.

Process

Located in Michigan, our lab has been successful with completing discovery studies amounting to thousands of patients.  OncoCellMDx has created a commercial platform that is undergoing validation studies using various sites located across the United States.

Method

NOVEL TECHNOLOGIES

OncoCellMDx has developed a technology to compare immunogenomic profiles in various oncology and non-oncology based indications … [Learn More]

INITIALLY TARGETING CANCER

OncoCellMDx’s Proprietary Technology has been extensively studied in Prostate Cancer with additional focus in other cancers … [Learn More]

OTHER INDICATIONS

Pilot studies have been performed in several other oncology and non-oncology based indications including metabolic disease, autoimmune disease, neurological disorders, cardiac disease among several others.

Platform